DOCSLIB.ORG

UCLA Health System

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
UCLA Health System UCLA Health System Clinical Exome Sequencing ENHANCED/TRIO PACKAGES Department of Pathology and Laboratory Medicine Feb 2013 UCLA Molecular Diagnostics Laboratories Page 1 Gene_Symbol cDNA_Length(bp) coverage Associated_Disease(GeneTests) MARC1 1042 77% . MARCH1 1200 100% . MARC2 1036 85% . MARCH2 757 100% . MARCH3 778 100% . MARCH4 1249 96% . MARCH5 861 95% . MARCH6 2837 99% . MARCH7 2151 100% . MARCH8 900 100% . MARCH9 1057 64% . MARCH10 2467 100% . MARCH11 1225 56% . SEPT1 1148 99% . SEPT2 1130 100% . SEPT3 1303 99% . SEPT4 1841 97% . SEPT5 1490 91% . SEPT6 1367 98% . SEPT7 1500 87% . SEPT8 1812 96% . SEPT9 3128 95% Hereditary Neuralgic Amyotrophy SEPT10 1409 98% . SEPT11 1330 98% . SEPT12 1113 96% . SEPT14 1335 100% . SEP15 654 100% . DEC1 229 100% . A1BG 1520 78% . A1CF 2166 100% . A2LD1 466 16% . A2M 4569 100% . A2ML1 4505 100% . UCLA Health System Clinical Exome Sequencing ENHANCED/TRIO PACKAGES Department of Pathology and Laboratory Medicine Feb 2013 UCLA Molecular Diagnostics Laboratories Page 2 Gene_Symbol cDNA_Length(bp) coverage Associated_Disease(GeneTests) A4GALT 1066 99% . A4GNT 1031 100% . AAAS 1705 100% Achalasia-Addisonianism-Alacrima Syndrome AAAS 1705 100% Choriodal Dystrophy, Central Areolar 2 AACS 2091 93% . AADAC 1220 100% . AADACL2 1226 100% . AADACL3 1073 100% . AADACL4 1240 100% . AADAT 1330 97% . AAGAB 988 100% . AAK1 2970 100% . AAMP 1349 99% . AANAT 1017 82% . AARS 2987 100% Charcot-Marie-Tooth Neuropathy Type 2 AARS 2987 100% Charcot-Marie-Tooth Neuropathy Type 2N AARS2 3046 99% Combined Oxidative Phosphorylation Deficiency 8 AARSD1 1990 94% . AASDH 3353 100% . AASDHPPT 954 100% . AASS 2873 100% Hyperlysinemia AASS 2873 100% Choriodal Dystrophy, Central Areolar 2 AATF 1731 95% . AATK 4330 61% . ABAT 1563 99% GABA-Transaminase Deficiency ABCA1 6982 100% Tangier Disease ABCA1 6982 100% Familial High Density Lipoprotein Deficiency ABCA1 6982 100% ABCA1-Associated Familial High Density Lipoprotein Deficiency ABCA10 4780 100% . ABCA12 8142 100% Autosomal Recessive Congenital Ichthyosis ABCA12 8142 100% ABCA12-Related Autosomal Recessive Congenital Ichthyosis ABCA12 8142 100% Harlequin Ichthyosis ABCA13 15425 99% . UCLA Health System Clinical Exome Sequencing ENHANCED/TRIO PACKAGES Department of Pathology and Laboratory Medicine Feb 2013 UCLA Molecular Diagnostics Laboratories Page 3 Gene_Symbol cDNA_Length(bp) coverage Associated_Disease(GeneTests) ABCA2 7792 83% . ABCA3 5235 96% Pulmonary Surfactant Metabolism Dysfunction ABCA3 5235 96% ABCA3-Related Pulmonary Surfactant Metabolism Dysfunction ABCA4 7022 100% Retinitis Pigmentosa, Autosomal Recessive ABCA4 7022 100% ABCA4-Related Stargardt Disease 1 ABCA4 7022 100% Age-Related Macular Degeneration ABCA4 7022 100% Retinitis Pigmentosa ABCA4 7022 100% Cone-Rod Dystrophy 3 ABCA4 7022 100% ABCA4-Related Retinitis Pigmentosa ABCA4 7022 100% Age-Related Macular Degeneration 2 ABCA4 7022 100% Stargardt Disease, Autosomal Recessive ABCA4 7022 100% Choriodal Dystrophy, Central Areolar 2 ABCA5 5081 100% . ABCA6 5006 100% . ABCA7 6625 90% . ABCA8 4894 100% . ABCA9 5027 100% . ABCB1 3951 100% . ABCB10 2269 77% . ABCB11 4074 100% Low Gamma-GT Familial Intrahepatic Cholestasis ABCB11 4074 100% ABCB11-Related Intrahepatic Cholestasis ABCB4 4201 100% Progressive Familial Intrahepatic Cholestasis 3 ABCB4 4201 100% Cholestasis, Familial Intrahepatic, of Pregnancy ABCB4 4201 100% Gallbladder Disease 1 ABCB5 4131 100% . ABCB6 2605 99% . ABCB7 2326 98% X-Linked Sideroblastic Anemia and Ataxia ABCB7 2326 98% Congenital Sideroblastic Anemia ABCB7 2326 98% Choriodal Dystrophy, Central Areolar 2 ABCB8 2221 100% . ABCB9 2345 86% . ABCC1 4720 98% . ABCC10 6054 100% . UCLA Health System Clinical Exome Sequencing ENHANCED/TRIO PACKAGES Department of Pathology and Laboratory Medicine Feb 2013 UCLA Molecular Diagnostics Laboratories Page 4 Gene_Symbol cDNA_Length(bp) coverage Associated_Disease(GeneTests) ABCC11 4265 99% . ABCC12 4196 100% . ABCC2 4766 100% Dubin-Johnson Syndrome ABCC2 4766 100% Choriodal Dystrophy, Central Areolar 2 ABCC3 5084 98% . ABCC4 4151 99% . ABCC5 4470 100% . ABCC6 4985 92% Pseudoxanthoma Elasticum ABCC6 4985 92% Choriodal Dystrophy, Central Areolar 2 ABCC8 4902 95% Familial Hyperinsulinism ABCC8 4902 95% ABCC8-Related Hyperinsulinism ABCC8 4902 95% Permanent Neonatal Diabetes Mellitus ABCC8 4902 95% ABCC8-Related Permanent Neonatal Diabetes Mellitus ABCC8 4902 95% ABCC8-Related Transient Neonatal Diabetes Mellitus 2 ABCC8 4902 95% Choriodal Dystrophy, Central Areolar 2 ABCC9 4944 100% Dilated Cardiomyopathy ABCC9 4944 100% ABCC9-Related Dilated Cardiomyopathy ABCC9 4944 100% Hypertrichotic Osteochondrodysplasia ABCD1 2278 82% Adrenoleukodystrophy, X-Linked ABCD1 2278 82% Choriodal Dystrophy, Central Areolar 2 ABCD2 2263 100% . ABCD3 2103 100% . ABCD4 1897 100% Disorders of Intracellular Cobalamin Metabolism ABCD4 1897 100% cbIJ ABCE1 1868 100% . ABCF1 2638 100% . ABCF2 2111 100% . ABCF3 2214 100% . ABCG1 2702 96% . ABCG2 2028 100% . ABCG4 1997 100% . ABCG5 2008 89% Sitosterolemia ABCG8 2074 97% Sitosterolemia UCLA Health System Clinical Exome Sequencing ENHANCED/TRIO PACKAGES Department of Pathology and Laboratory Medicine Feb 2013 UCLA Molecular Diagnostics Laboratories Page 5 Gene_Symbol cDNA_Length(bp) coverage Associated_Disease(GeneTests) ABHD1 1254 100% . ABHD10 941 100% . ABHD11 1112 98% . ABHD12 1311 85% Polyneuropathy, Hearing Loss, Ataxia, Retinitis Pigmentosa, and Cataract ABHD12B 920 88% . ABHD13 1018 100% . ABHD14A 836 91% . ABHD14B 645 100% . ABHD15 1415 86% . ABHD16A 1918 100% . ABHD16B 1414 55% . ABHD2 1314 100% . ABHD3 1266 96% . ABHD4 1057 97% . ABHD5 1078 100% Chanarin-Dorfman Syndrome ABHD6 1046 100% . ABHD8 1336 100% . ABI1 1811 97% . ABI2 1468 100% . ABI3 1305 82% . ABI3BP 3368 100% . ABL1 3577 98% . ABL2 7214 99% . ABLIM1 2673 100% . ABLIM2 2402 99% . ABLIM3 2144 100% . ABO 1092 97% . ABP1 2272 100% . ABR 3000 93% . ABRA 1154 100% . ABT1 831 100% . ABTB1 1649 97% . ABTB2 3146 80% . UCLA Health System Clinical Exome Sequencing ENHANCED/TRIO PACKAGES Department of Pathology and Laboratory Medicine Feb 2013 UCLA Molecular Diagnostics Laboratories Page 6 Gene_Symbol cDNA_Length(bp) coverage Associated_Disease(GeneTests) ACAA1 1323 90% . ACAA2 1234 92% . ACACA 7827 100% . ACACB 7585 100% . ACAD10 3357 97% . ACAD11 2423 100% . ACAD8 1292 94% Isobutyryl-CoA Dehydrogenase Deficiency ACAD9 1938 100% Mitochondrial Respiratory Chain Complex I Deficiency (nuclear genes) ACAD9 1938 100% Acyl-CoA Dehydrogenase 9 Deficiency ACADL 1337 96% Long-Chain Acyl-CoA Dehydrogenase Deficiency ACADM 1430 100% Medium Chain Acyl-Coenzyme A Dehydrogenase Deficiency ACADM 1430 100% Choriodal Dystrophy, Central Areolar 2 ACADS 1279 93% Short Chain Acyl-CoA Dehydrogenase Deficiency ACADS 1279 93% Choriodal Dystrophy, Central Areolar 2 ACADSB 1343 97% Acyl-CoA Dehydrogenase, Short/Branched Chain Deficiency ACADVL 2048 95% Very Long Chain Acyl-Coenzyme A Dehydrogenase Deficiency ACADVL 2048 95% Choriodal Dystrophy, Central Areolar 2 ACAN 7661 89% . ACAP1 2311 93% . ACAP2 2429 98% . ACAP3 2601 72% . ACAT1 1332 94% Ketothiolase Deficiency ACAT1 1332 94% Choriodal Dystrophy, Central Areolar 2 ACAT2 1230 100% . ACBD3 1619 87% . ACBD4 1490 98% . ACBD5 1800 100% . ACBD6 881 100% . ACBD7 283 100% . ACCN1 2291 92% . ACCN2 2003 99% . ACCN3 2151 97% . ACCN4 2041 91% . UCLA Health System Clinical Exome Sequencing ENHANCED/TRIO PACKAGES Department of Pathology and Laboratory Medicine Feb 2013 UCLA Molecular Diagnostics Laboratories Page 7 Gene_Symbol cDNA_Length(bp) coverage Associated_Disease(GeneTests) ACCN5 1558 100% . ACCS 1562 99% . ACCSL 1763 100% . ACD 1926 100% . ACE 4224 92% Cardiovascular Disease Risk Factor (Angiotensin Converting Enzyme (ACE)) ACE 4224 92% Renal Tubular Dysgenesis, ACE-Related ACE 4224 92% Choriodal Dystrophy, Central Areolar 2 ACE2 2490 100% . ACER1 819 99% . ACER2 852 91% . ACER3 848 87% . ACHE 1996 93% . ACIN1 4544 99% . ACLY 3418 100% . ACMSD 1051 100% . ACN9 386 100% . ACO1 2750 100% . ACO2 2415 100% . ACOT1 1278 65% . ACOT11 2052 90% . ACOT12 1728 94% . ACOT13 451 96% . ACOT2 1464 95% . ACOT4 1278 88% . ACOT6 632 100% . ACOT7 1437 92% . ACOT8 984 100% . ACOT9 1411 98% . ACOX1 2368 100% Pseudoneonatal Adrenoleukodystrophy ACOX1 2368 100% Choriodal Dystrophy, Central Areolar 2 ACOX2 2102 100% . ACOX3 2262 92% . ACOXL 1811 100% . UCLA Health System Clinical Exome Sequencing ENHANCED/TRIO PACKAGES Department of Pathology and Laboratory Medicine Feb 2013 UCLA Molecular Diagnostics Laboratories Page 8 Gene_Symbol cDNA_Length(bp) coverage Associated_Disease(GeneTests) ACP1 1202 100% . ACP2 1539 99% . ACP5 994 100% . ACP6 1327 95% . ACPL2 1463 100% . ACPP 1521 100% . ACPT 1325 75% . ACR 1286 89% . ACRBP 1672 98% . ACRC 2124 99% . ACRV1 2834 100% . ACSBG1 2324 100% . ACSBG2 2053 97% . ACSF2 1912 94% . ACSF3 1767 97% . ACSL1 2177 100% . ACSL3 2219 100% . ACSL4 2547 100% X-Linked Mental Retardation 63 ACSL5 2493 100% . ACSL6 3149 100% . ACSM1 1786 100% . ACSM2A 1786 100% . ACSM2B 1786 100% . ACSM3 2156 100% . ACSM4 1795 100% . ACSM5 1792 100% . ACSS1 2375 97% . ACSS2 2421 92% . ACSS3 2125 99% . ACTA1 1158 100% Nemaline Myopathy ACTA1 1158 100% Congenital Fiber-Type Disproportion ACTA1 1158 100% ACTA1-Related Congenital Fiber-Type Disproportion ACTA1 1158 100% ACTA1-Related Nemaline Myopathy UCLA Health System Clinical Exome Sequencing ENHANCED/TRIO PACKAGES Department of Pathology and Laboratory Medicine Feb 2013 UCLA Molecular Diagnostics Laboratories Page 9 Gene_Symbol cDNA_Length(bp) coverage Associated_Disease(GeneTests) ACTA1 1158 100% Childhood
Load more

Recommended publications
  • Moderate the MAOA-L Allele Expression with CRISPR/Cas9 System
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 23 April 2018 doi:10.20944/preprints201804.0275.v1 1 Review 2 Moderate the MAOA-L Allele Expression with CRISPR/Cas9 System 3 Martin L. Nelwan 4 Department of Animal Science – Other 5 Nelwan Institution for Human Resource Development 6 Jl. A. Yani No. 24 7 Palu, Sulawesi Tengah, Indonesia 8 Email: [email protected] 9 Abstract: Antisocial behavior is a behavior disorder inherited according to the inheritance of X-linked 10 chromosome. Mutations in the MAOA gene can cause different behaviors in humans. These can comprise 11 violent behavior or antisocial behavior. Low MAOA (MAOA-L) allele activity can cause antisocial 12 behavior in both healthy and unhealthy people. Antisocial from healthy males can originate from 13 maltreatment during childhood. There are no drugs for the treatment of antisocial behavior permanently 14 at this time. MAOA inhibitor can reverse antisocial behavior in animal models. To cure antisocial 15 behavior in the future, the CRISPR/Cas9 system in combination with iPSCs or ssODN methods for 16 instance can be used. This system has succeeded to correct erroneous segments in the F8 gene and F9 17 gene. Both genes occupy the X chromosome. The MAOA gene also occupies the X chromosome. It seems 18 that CRISPR/Cas9 system may be a beneficial tool to edit erroneous segments in the MAOA gene to treat 19 antisocial behavior. 20 Keywords: advanced therapy, aggressive, antisocial, behavior, MAOA. 21 22 1. Introduction 23 Antisocial behavior is a hereditary disorder inherited through an X-linked recessive inheritance 24 pattern.
    [Show full text]
  • Funktionelle in Vitro Und in Vivo Charakterisierung Des Putativen Tumorsuppressorgens SFRP1 Im Humanen Mammakarzinom
    Funktionelle in vitro und in vivo Charakterisierung des putativen Tumorsuppressorgens SFRP1 im humanen Mammakarzinom Von der Fakult¨at fur¨ Mathematik, Informatik und Naturwissenschaften der RWTH Aachen University zur Erlangung des akademischen Grades einer Doktorin der Naturwissenschaften genehmigte Dissertation vorgelegt von Diplom-Biologin Laura Huth (geb. Franken) aus Julich¨ Berichter: Universit¨atsprofessor Dr. rer. nat. Edgar Dahl Universit¨atsprofessor Dr. rer. nat. Ralph Panstruga Tag der mundlichen¨ Prufung:¨ 6. August 2014 Diese Dissertation ist auf den Internetseiten der Hochschulbibliothek online verfugbar.¨ Zusammenfassung Krebserkrankungen stellen weltweit eine der h¨aufigsten Todesursachen dar. Aus diesem Grund ist die Aufkl¨arung der zugrunde liegenden Mechanismen und Ur- sachen ein essentielles Ziel der molekularen Onkologie. Die Tumorforschung der letzten Jahre hat gezeigt, dass die Entstehung solider Karzinome ein Mehrstufen- Prozess ist, bei dem neben Onkogenen auch Tumorsuppresorgene eine entschei- dende Rolle spielen. Viele der heute bekannten Gene des WNT-Signalweges wur- den bereits als Onkogene oder Tumorsuppressorgene charakterisiert. Eine Dere- gulation des WNT-Signalweges wird daher mit der Entstehung und Progression vieler humaner Tumorentit¨aten wie beispielsweise auch dem Mammakarzinom, der weltweit h¨aufigsten Krebserkrankung der Frau, assoziiert. SFRP1, ein nega- tiver Regulator der WNT-Signalkaskade, wird in Brusttumoren haupts¨achlich durch den epigenetischen Mechanismus der Promotorhypermethylierung
    [Show full text]
  • EXTENDED CARRIER SCREENING Peace of Mind for Planned Pregnancies
    Focusing on Personalised Medicine EXTENDED CARRIER SCREENING Peace of Mind for Planned Pregnancies Extended carrier screening is an important tool for prospective parents to help them determine their risk of having a child affected with a heritable disease. In many cases, parents aren’t aware they are carriers and have no family history due to the rarity of some diseases in the general population. What is covered by the screening? Genomics For Life offers a comprehensive Extended Carrier Screening test, providing prospective parents with the information they require when planning their pregnancy. Extended Carrier Screening has been shown to detect carriers who would not have been considered candidates for traditional risk- based screening. With a simple mouth swab collection, we are able to test for over 419 genes associated with inherited diseases, including Fragile X Syndrome, Cystic Fibrosis and Spinal Muscular Atrophy. The assay has been developed in conjunction with clinical molecular geneticists, and includes genes listed in the NIH Genetic Test Registry. For a list of genes and disorders covered, please see the reverse of this brochure. If your gene of interest is not covered on our Extended Carrier Screening panel, please contact our friendly team to assist you in finding a gene test panel that suits your needs. Why have Extended Carrier Screening? Extended Carrier Screening prior to pregnancy enables couples to learn about their reproductive risk and consider a complete range of reproductive options, including whether or not to become pregnant, whether to use advanced reproductive technologies, such as preimplantation genetic diagnosis, or to use donor gametes.
    [Show full text]
  • A Genome-Wide Association Study of Body Mass Index
    International Journal of Epidemiology, 2015, 700–712 doi: 10.1093/ije/dyv077 Advance Access Publication Date: 7 May 2015 Original article Genetic Epidemiology A genome-wide association study of body mass index across early life and childhood Nicole M Warrington,1,2* Laura D Howe,3,4* Lavinia Paternoster,3,4 Marika Kaakinen,5,6,7 Sauli Herrala,6 Ville Huikari,6 Yan Yan Wu,8 Downloaded from John P Kemp,2,3 Nicholas J Timpson,3,4 Beate St Pourcain,3,4 George Davey Smith,3,4 Kate Tilling,3,4 Marjo-Riitta Jarvelin,5,6,9,10,11 Craig E Pennell,1 David M Evans,2,3,4 Debbie A Lawlor,3,4 Laurent Briollais8,† and Lyle J Palmer12,† http://ije.oxfordjournals.org/ 1School of Women’s and Infants’ Health, University of Western Australia, Perth, WA, Australia, 2University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, QLD, Australia, 3MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK, 4School of Social and Community Medicine, University of Bristol, Bristol, UK, 5Biocenter Oulu, and 6Institute of Health Sciences, University of Oulu, Oulu, Finland, 7Department of Genomics of Common Disease, School of Public Health, Imperial College London, London, UK, 8Lunenfeld-Tanenbaum Research Institute, Mount 9 Sinai Hospital, Toronto, ON, Canada, Department of Children and Young People and Families, National at MPI Psycholinguistics on September 22, 2015 Institute for Health and Welfare, Oulu, Finland, 10Department of Epidemiology and Biostatistics, MRC- HPA Centre for Environment and Health, School of Public Health, Imperial College London, London, UK, 11Unit of Primary Care, Oulu University Hospital, Oulu, Finland and 12The Joanna Briggs Institute, The Robinson Research Institute, and School of Translational Health Science, University of Adelaide, Adelaide, SA, Australia *Corresponding authors.
    [Show full text]
  • Abstracts from the 9Th Biennial Scientific Meeting of The
    International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 DOI 10.1186/s13633-017-0054-x MEETING ABSTRACTS Open Access Abstracts from the 9th Biennial Scientific Meeting of the Asia Pacific Paediatric Endocrine Society (APPES) and the 50th Annual Meeting of the Japanese Society for Pediatric Endocrinology (JSPE) Tokyo, Japan. 17-20 November 2016 Published: 28 Dec 2017 PS1 Heritable forms of primary bone fragility in children typically lead to Fat fate and disease - from science to global policy a clinical diagnosis of either osteogenesis imperfecta (OI) or juvenile Peter Gluckman osteoporosis (JO). OI is usually caused by dominant mutations affect- Office of Chief Science Advsor to the Prime Minister ing one of the two genes that code for two collagen type I, but a re- International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):PS1 cessive form of OI is present in 5-10% of individuals with a clinical diagnosis of OI. Most of the involved genes code for proteins that Attempts to deal with the obesity epidemic based solely on adult be- play a role in the processing of collagen type I protein (BMP1, havioural change have been rather disappointing. Indeed the evidence CREB3L1, CRTAP, LEPRE1, P4HB, PPIB, FKBP10, PLOD2, SERPINF1, that biological, developmental and contextual factors are operating SERPINH1, SEC24D, SPARC, from the earliest stages in development and indeed across generations TMEM38B), or interfere with osteoblast function (SP7, WNT1). Specific is compelling. The marked individual differences in the sensitivity to the phenotypes are caused by mutations in SERPINF1 (recessive OI type obesogenic environment need to be understood at both the individual VI), P4HB (Cole-Carpenter syndrome) and SEC24D (‘Cole-Carpenter and population level.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Molecular Characterization and Structural Implications of 25 New ABCB4 Mutations in Progressive Familial Intrahepatic Cholestasis Type 3 (PFIC3)
    European Journal of Human Genetics (2007) 15, 1230–1238 & 2007 Nature Publishing Group All rights reserved 1018-4813/07 $30.00 www.nature.com/ejhg ARTICLE Molecular characterization and structural implications of 25 new ABCB4 mutations in progressive familial intrahepatic cholestasis type 3 (PFIC3) Dario Degiorgio1, Carla Colombo2, Manuela Seia1, Luigi Porcaro1, Lucy Costantino1, Laura Zazzeron2, Domenico Bordo3 and Domenico A Coviello*,1 1Laboratorio di Genetica Medica, Fondazione IRCCS, Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milano, Italy; 2Centro Fibrosi Cistica, Universita` degli Studi di Milano, Fondazione IRCCS, Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milano, Italy; 3Bioinformatica e Proteomica Strutturale, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy Progressive familial intrahepatic cholestasis type 3 (PFIC3) is an autosomal-recessive disorder due to mutations in the ATP-binding cassette, subfamily B, member 4 gene (ABCB4). ABCB4 is the liver-specific membrane transporter of phosphatidylcholine, a major and exclusive component of mammalian bile. The disease is characterized by early onset of cholestasis with high serum c-glutamyltranspeptidase activity, which progresses into cirrhosis and liver failure before adulthood. Presently, about 20 distinct ABCB4 mutations associated to PFIC3 have been described. We report the molecular characterization of 68 PFIC3 index cases enrolled in a multicenter study, which represents the largest cohort of PFIC3 patients screened for ABCB4 mutations to date. We observed 31 mutated ABCB4 alleles in 18 index cases with 29 distinct mutations, 25 of which are novel. Despite the lack of structural information on the ABCB4 protein, the elucidation of the three-dimensional structure of bacterial homolog allows the three-dimensional model of ABCB4 to be built by homology modeling and the position of the mutated amino-acids in the protein tertiary structure to be located.
    [Show full text]
  • Genes in Eyecare Geneseyedoc 3 W.M
    Genes in Eyecare geneseyedoc 3 W.M. Lyle and T.D. Williams 15 Mar 04 This information has been gathered from several sources; however, the principal source is V. A. McKusick’s Mendelian Inheritance in Man on CD-ROM. Baltimore, Johns Hopkins University Press, 1998. Other sources include McKusick’s, Mendelian Inheritance in Man. Catalogs of Human Genes and Genetic Disorders. Baltimore. Johns Hopkins University Press 1998 (12th edition). http://www.ncbi.nlm.nih.gov/Omim See also S.P.Daiger, L.S. Sullivan, and B.J.F. Rossiter Ret Net http://www.sph.uth.tmc.edu/Retnet disease.htm/. Also E.I. Traboulsi’s, Genetic Diseases of the Eye, New York, Oxford University Press, 1998. And Genetics in Primary Eyecare and Clinical Medicine by M.R. Seashore and R.S.Wappner, Appleton and Lange 1996. M. Ridley’s book Genome published in 2000 by Perennial provides additional information. Ridley estimates that we have 60,000 to 80,000 genes. See also R.M. Henig’s book The Monk in the Garden: The Lost and Found Genius of Gregor Mendel, published by Houghton Mifflin in 2001 which tells about the Father of Genetics. The 3rd edition of F. H. Roy’s book Ocular Syndromes and Systemic Diseases published by Lippincott Williams & Wilkins in 2002 facilitates differential diagnosis. Additional information is provided in D. Pavan-Langston’s Manual of Ocular Diagnosis and Therapy (5th edition) published by Lippincott Williams & Wilkins in 2002. M.A. Foote wrote Basic Human Genetics for Medical Writers in the AMWA Journal 2002;17:7-17. A compilation such as this might suggest that one gene = one disease.
    [Show full text]
  • Cellular and Molecular Signatures in the Disease Tissue of Early
    Cellular and Molecular Signatures in the Disease Tissue of Early Rheumatoid Arthritis Stratify Clinical Response to csDMARD-Therapy and Predict Radiographic Progression Frances Humby1,* Myles Lewis1,* Nandhini Ramamoorthi2, Jason Hackney3, Michael Barnes1, Michele Bombardieri1, Francesca Setiadi2, Stephen Kelly1, Fabiola Bene1, Maria di Cicco1, Sudeh Riahi1, Vidalba Rocher-Ros1, Nora Ng1, Ilias Lazorou1, Rebecca E. Hands1, Desiree van der Heijde4, Robert Landewé5, Annette van der Helm-van Mil4, Alberto Cauli6, Iain B. McInnes7, Christopher D. Buckley8, Ernest Choy9, Peter Taylor10, Michael J. Townsend2 & Costantino Pitzalis1 1Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. Departments of 2Biomarker Discovery OMNI, 3Bioinformatics and Computational Biology, Genentech Research and Early Development, South San Francisco, California 94080 USA 4Department of Rheumatology, Leiden University Medical Center, The Netherlands 5Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology & Immunology Center, Amsterdam, The Netherlands 6Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari, Cagliari, Italy 7Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8TA, UK 8Rheumatology Research Group, Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham B15 2WB, UK 9Institute of
    [Show full text]
  • ABCB6 Is a Porphyrin Transporter with a Novel Trafficking Signal That Is Conserved in Other ABC Transporters Yu Fukuda University of Tennessee Health Science Center
    University of Tennessee Health Science Center UTHSC Digital Commons Theses and Dissertations (ETD) College of Graduate Health Sciences 12-2008 ABCB6 Is a Porphyrin Transporter with a Novel Trafficking Signal That Is Conserved in Other ABC Transporters Yu Fukuda University of Tennessee Health Science Center Follow this and additional works at: https://dc.uthsc.edu/dissertations Part of the Chemicals and Drugs Commons, and the Medical Sciences Commons Recommended Citation Fukuda, Yu , "ABCB6 Is a Porphyrin Transporter with a Novel Trafficking Signal That Is Conserved in Other ABC Transporters" (2008). Theses and Dissertations (ETD). Paper 345. http://dx.doi.org/10.21007/etd.cghs.2008.0100. This Dissertation is brought to you for free and open access by the College of Graduate Health Sciences at UTHSC Digital Commons. It has been accepted for inclusion in Theses and Dissertations (ETD) by an authorized administrator of UTHSC Digital Commons. For more information, please contact [email protected]. ABCB6 Is a Porphyrin Transporter with a Novel Trafficking Signal That Is Conserved in Other ABC Transporters Document Type Dissertation Degree Name Doctor of Philosophy (PhD) Program Interdisciplinary Program Research Advisor John D. Schuetz, Ph.D. Committee Linda Hendershot, Ph.D. James I. Morgan, Ph.D. Anjaparavanda P. Naren, Ph.D. Jie Zheng, Ph.D. DOI 10.21007/etd.cghs.2008.0100 This dissertation is available at UTHSC Digital Commons: https://dc.uthsc.edu/dissertations/345 ABCB6 IS A PORPHYRIN TRANSPORTER WITH A NOVEL TRAFFICKING SIGNAL THAT
    [Show full text]
  • UNIVERSITY of CALIFORNIA RIVERSIDE Investigations Into The
    UNIVERSITY OF CALIFORNIA RIVERSIDE Investigations into the Role of TAF1-mediated Phosphorylation in Gene Regulation A Dissertation submitted in partial satisfaction of the requirements for the degree of Doctor of Philosophy in Cell, Molecular and Developmental Biology by Brian James Gadd December 2012 Dissertation Committee: Dr. Xuan Liu, Chairperson Dr. Frank Sauer Dr. Frances M. Sladek Copyright by Brian James Gadd 2012 The Dissertation of Brian James Gadd is approved Committee Chairperson University of California, Riverside Acknowledgments I am thankful to Dr. Liu for her patience and support over the last eight years. I am deeply indebted to my committee members, Dr. Frank Sauer and Dr. Frances Sladek for the insightful comments on my research and this dissertation. Thanks goes out to CMDB, especially Dr. Bachant, Dr. Springer and Kathy Redd for their support. Thanks to all the members of the Liu lab both past and present. A very special thanks to the members of the Sauer lab, including Silvia, Stephane, David, Matt, Stephen, Ninuo, Toby, Josh, Alice, Alex and Flora. You have made all the years here fly by and made them so enjoyable. From the Sladek lab I want to thank Eugene, John, Linh and Karthi. Special thanks go out to all the friends I’ve made over the years here. Chris, Amber, Stephane and David, thank you so much for feeding me, encouraging me and keeping me sane. Thanks to the brothers for all your encouragement and prayers. To any I haven’t mentioned by name, I promise I haven’t forgotten all you’ve done for me during my graduate years.
    [Show full text]
  • TITLE PAGE Oxidative Stress and Response to Thymidylate Synthase
    Downloaded from molpharm.aspetjournals.org at ASPET Journals on October 2, 2021 -Targeted -Targeted 1 , University of of , University SC K.W.B., South Columbia, (U.O., Carolina, This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted.
    [Show full text]